BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30694722)

  • 1. Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice.
    Wang F; Luo Y; Tian X; Ma S; Sun Y; You C; Gong Y; Xie C
    Radiat Res; 2019 Mar; 191(3):271-277. PubMed ID: 30694722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
    Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
    J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues.
    Myers CJ; Lu B
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1129-1136. PubMed ID: 29165283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
    Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
    Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of cisplatin alone or combined with monoclonal anti-programmed death ligand-1 antibody on lung adenocarcinoma cell line SPCA-1 and T lymphocytes].
    Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):416-20. PubMed ID: 25200040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Effects of Nanoscale CaO
    Wang Y; Ju S; Zhou H; Bai Y; Zhou C; Liu J; Dong X; Zheng C
    Int J Nanomedicine; 2024; 19():137-154. PubMed ID: 38196507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
    Levingston CA; Young MR
    Int J Cancer; 2017 Apr; 140(7):1609-1619. PubMed ID: 27914100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.
    Kao CJ; Wurz GT; Lin YC; Vang DP; Griffey SM; Wolf M; DeGregorio MW
    Cancer Immunol Res; 2015 Jul; 3(7):741-50. PubMed ID: 25672395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-PD-1 Antibody Administration following Hip Fracture Surgery Reverses Immune Dysfunction and Decreases Susceptibility to Infection.
    Zhang H; Chen C; He J; Zhang J; Liu Z; Sun T
    Mediators Inflamm; 2019; 2019():8492090. PubMed ID: 31073275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.
    Hamada N; Yanagihara T; Suzuki K; Ogata-Suetsugu S; Harada E; Mikumo H; Arimura-Omori M; Nakanishi Y
    Biochem Biophys Res Commun; 2017 Sep; 491(3):656-661. PubMed ID: 28756224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination radiotherapy and cantharidin inhibits lung cancer growth through altering tumor infiltrating lymphocytes.
    Zhang Y; Yang SL; Zhang HR; Gao L; Gao X; Liu PJ; Yi ZY; Li N; Xu ZQ
    Future Oncol; 2017 Jun; 13(13):1173-1180. PubMed ID: 28498036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
    Wang X; Schoenhals JE; Li A; Valdecanas DR; Ye H; Zang F; Tang C; Tang M; Liu CG; Liu X; Krishnan S; Allison JP; Sharma P; Hwu P; Komaki R; Overwijk WW; Gomez DR; Chang JY; Hahn SM; Cortez MA; Welsh JW
    Cancer Res; 2017 Feb; 77(4):839-850. PubMed ID: 27821490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.